Impact of Adipose Tissue in COVID-19 (COVIFAT)

Assistance Publique - Hôpitaux de Paris

Status: Unknown

Conditions: Covid19

Treatments: Other: Adipose tissue

Study type: Observational

Funder types: Other

Identifiers

NCT04639440

APHP200983

2020-A02403-36 (Other Identifier)

Details and patient eligibility

About

Overweight or obese patients are particularly exposed to severe forms of COVID-19. Few data suggest that adipose tissue infected with SARS-CoV-2 could be involved in the onset of the cytokine storm seen in severe forms of COVID-19. The aim of this study is to determine the pathogenesis of SARS-CoV-2-infection of adipose tissue. In particular the investigators will study how this virus enters the adipocyte and how it modulates metabolism and inflammation in the adipose tissue. From these data, the investigators hope to determine at the adipose tissue level, original therapeutic targets to modulate the effects of SARS-CoV-2 at the systemic level.

Enrollment: 60 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age greater than or equal to 18 years
• All patients who are obese or overweight (> 25 kg/m2) or non-obese (< or = 25 kg/m2) operated for abdominal vascular surgery
• Beneficiary or entitled to a social security scheme (except AME)

Exclusion criteria

• Pregnant or breastfeeding woman
• Patient refusal
• Patient deprived of liberty or subject to a legal protection measure (guardianship, curatorship)

Trial design

60 participants in 2 patient groups

Obese or overweight patients

Treatment:

Other: Adipose tissue

Patients without overweight

Treatment:

Other: Adipose tissue